623 Results
Sort By:
Published on December 13, 2023
New research highlights the different mechanisms of action of two immunotherapy combination therapies for advanced melanoma. An anti-PD-1/LAG-3 drug combination required the presence of CD4 T cells for its anticancer effects, in both cutaneous melanoma and brain metastases melanoma, while the anti-PD-1/CTLA-4 combination did not. “These observations are of particular…
Published on November 7, 2023
An AI-driven pre-screening test for colorectal cancer (CRC) treatment has taken a key step forward with a validation study, as reported in Nature Communications. Owkin’s MSIntuit test showed almost 99% sensitivity for detecting those patients most likely to respond to immunotherapy. “Our solution represents the first step towards the development…
Published on October 25, 2023
Adding immunotherapy to chemotherapy almost doubled survival in patients with an advanced type of bladder cancer, in the first of its kind trial reported in The New England Journal of Medicine and at the annual meeting of the European Society for Medical Oncology (ESMO). The multicenter, international study was co-led by Mount Sinai…
Published on October 23, 2023
New research published today from investigators at the University of Texas MD Anderson Cancer Center shows that non-small cell lung cancer (NSCLC) outcomes were significantly improved by a regimen of pre-surgical immunotherapy plus chemotherapy followed by post-surgical immunotherapy. The results of the Phase III trial, published today in the New…
Published on October 20, 2023
Investigators at the University of Texas MD Anderson Cancer Center has developed a potentially groundbreaking method for enhancing immunotherapy responses in glioblastoma by using extracellular vesicles loaded with messenger RNA (mRNA). This new approach, detailed in Nature Communications, has solved some of the hurdles faced by mRNA-based therapy approaches for…
Published on October 12, 2023
Researchers at the University of California, Los Angeles (UCLA) have developed a new treatment method using a nanocapsule to deliver the enzyme lactate oxidase into solid tumors, improving anti-tumoral immune response and immune checkpoint inhibitor therapy efficacy.Reporting in Science Translational Medicine, scientists are targeting lactate—a chemical produced by cancer cells…
Published on October 4, 2023
A team of investigators at Vanderbilt-Ingram Cancer Center, reporting in Cancer Discovery, has discovered a druggable target on natural killer cells that could create a therapeutic response in patients with immunotherapy-resistant triple-negative breast cancer. While immunotherapy has shown promise across a range of cancers and tumor types, only about 15%…
Published on September 20, 2023
Although the treatment landscape for patients with advanced non-small-cell lung cancer (NSCLC) has evolved dramatically over the last decade, translation of these therapeutic advances to earlier-stage NSCLC has lagged. However, results of the Phase II NeoCOAST trial show that combination immunotherapy with anti-PD-L1 durvalumab and one of several other immunotherapies…
Published on September 19, 2023
Investigators at Dana-Farber Cancer Institute (DFCI), reporting in Cell Reports Medicine, say that a deep learning model they have developed can identify previously underappreciated features in clear cell renal carcinoma (ccRCC) from a two-dimensional pathology slide including tumor microheterogeneity that could help predict this rare kidney cancer’s response to immunotherapy.…
Published on September 13, 2023
Research presented at the International Association for the Study of Lung Cancer 2023 World Conference has shown that first-line immunotherapy with nivolumab plus ipilimumab gives rise to durable survival benefits in a significant proportion of patients with advanced non-small-cell lung cancer (NSCLC). The 6-year update of the CheckMate 227 trial,…
Published on September 6, 2023
New evidence suggests lymph nodes play a key role in why tumors that have spread to the brain respond to immunotherapy, while glioblastoma, which originates in the brain, does not. “Typically, antigen presenting cells (e.g., conventional dendritic cells, cDCs) are recruited to the tumor, where they phagocytose dead or dying tumor…
Published on August 31, 2023
The location of cytotoxic T cells, in and around tumors, may help predict lung cancer patient survival and treatment response, according to work from University of Edinburgh researchers. Their findings, they say, could help to pave the way for improved immunotherapies. Such treatments are revolutionary in their ability to cure…
Published on August 23, 2023
A multicenter Phase II clinical trial showed that combination immunotherapy drug therapy with ipilimumab (an anti-CTLA-4 drug) and nivolumab (an anti-PD-1 therapy) is an effective second-line therapy for patients with melanoma that has progressed on PD-1 inhibitors alone. It is the first randomized study showing that continuing PD-1 therapy beyond…
Published on August 23, 2023
Etcembly, a U.K. biotech, has developed a new immunotherapy to target hard-to-treat cancers using generative artificial intelligence (AI) similar to that used to create ChatGPT. According to the company, this is the first time a candidate immunotherapy has been designed by generative AI. The new therapeutic candidate is a bispecific…
Published on August 16, 2023
Salk scientists have found the immunotherapy treatment anti-CTLA-4 leads to considerably greater survival of mice with mesenchymal glioblastoma. Furthermore, they discovered that this therapy relied on CD4+ T cells infiltrating the brain and triggering the tumor-destructive activities of immune cells called microglia, which permanently reside in the brain. Published in Immunity,…